Biotherapeutic Propensity of the Probiotic Strains Isolated from Human Gut Microbiota Against Enteric Infection by Salmonella Typhimurium KCTC 2514

Abstract

Enteric infection is the major cause of mortality and associated complications in the growth and subsequent development of the children below the age of five. The alarming mortality rate of four fifty thousand deaths per year in the developing Asian countries has captured special attention towards preventive strategies and biotherapeutic intervention which is sustainable. The enteric infection by pathogens causes associated complications like antioxidant stress in the colon leading to inflammatory condition and leaky gut which causes poor absorption of nutrients which in turn leads to malnutrition and poor response to conventional therapeutic drugs. Our current research work is focussed towards identifying the niche beneficial bacterial species from the human gut microbiome of Rourkela region, Odisha, India towards the development of biotherapeutic probiotic strains which could alleviate enteric infection and associated complications through the modulation of the gut microbiota and production of beneficial metabolites, which helps in the recovery and rejuvenation of the damaged gut associated with enteric infection. In our study we have attempted to isolate probiotic strains which produces short chain fatty acids and antioxidants under simulated colonic conditions. The ability of the strains Lactobacillus plantarum strains SAE33a and MI89 to inhibit the growth of the enteric pathogen Salmonella enterica subsp., enterica serovar typhimurium (KCTC 2514) is investigated by co-culturing them in the simulated colonic conditions. The reduction of pathogen count and associated lipopolysaccharides (LPS) reduction upon co-culturing and the production of beneficial amount of short chain fatty acids and increased antioxidant profile under simulated colonic conditions hold the promise of the strains to be used in therapeutic intervention after in-vivo efficacy studies.